The role of the bacterial microbiome in lung disease

Expert Review of Respiratory Medicine

Volumn 7, Issue 3, 2013, Pages 245-257

  Dickson, Robert P ^a   Erb Downward, John R ^a   Huffnagle, Gary B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

16S; bacteria; infection; lung microbiome; microbial diversity; pathogenesis; pulmonary disease; pyrosequencing

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT;

ALLERGIC AIRWAY INFLAMMATION; ARTIFICIAL VENTILATION; ASTHMA; BACTERIAL VIRULENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CYSTIC FIBROSIS; DIARRHEA; DISEASE SEVERITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNITY; INFECTIOUS DIARRHEA; INTERSTITIAL PNEUMONIA; LOWER RESPIRATORY TRACT; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; MICROFLORA; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84878700358     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.13.24     Document Type: Review

References (116)

1. Mizgerd JP. Lung infection-a public health priority. PLoS Med. 3(2), e76 (2006).
2. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 312(5778), 1355-1359 (2006).
3. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13(4), 260-270 (2012).
4. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133(3), 610-617 (2008).
5. Suau A, Bonnet R, Sutren M, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl. Environ. Microbiol. 65(11), 4799-4807 (1999).
6. Liu Z, DeSantis TZ, Andersen GL, Knight R. Accurate taxonomy assignments from 16S rRNA sequences produced by highly parallel pyrosequencers. Nucleic Acids Res. 36(18), e120 (2008).
7. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75(23), 7537-7541 (2009).
8. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 308(5728), 1635-1638 (2005).
9. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the 'healthy' smoker and in COPD. PLoS ONE 6(2), e16384 (2011).
10. Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc. Natl Acad. Sci. USA 109(34), 13769-13774 (2012).
11. Rudkjøbing VB, Thomsen TR, Alhede M, et al. True microbiota involved in chronic lung infection of cystic fibrosis patients found by culturing and 16S rRNA gene analysis. J. Clin. Microbiol. 49(12), 4352-4355 (2011).
12. Cabrera-Rubio R, Garcia-Núñez M, Setó L, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J. Clin. Microbiol. 50(11), 3562-3568 (2012).
13. Charlson ES, Bittinger K, Chen J, et al. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS ONE 7(9), e42786 (2012).
14. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 184(8), 957-963 (2011).
15. Hubbell SP. Neutral theory in community ecology and the hypothesis of functional equivalence. Funct. Ecol. 19(1), 166-172 (2005).
16. Hubbell SP. The Unified Neutral Theory of Biodiversity and Biogeography (MPB-32). Princeton University Press, NJ, USA (2008).
17. Morris A, Beck JM, Schloss PD, et al.; on behalf of the Lung HIV Microbiome Project. Comparison of the respiratory microbiome in healthy non-smokers and smokers. Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201210-1913OC (2013) (Epub ahead of print).
18. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS ONE 5(1), e8578 (2010).
19. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107(26), 11971-11975 (2010).
20. Capone KA, Dowd SE, Stamatas GN, Nikolovski J. Diversity of the human skin microbiome early in life. J. Invest. Dermatol. 131(10), 2026-2032 (2011).
21. Madan JC, Koestler DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 3(4), e00251-72 (2012).
22. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 7(10), e47305 (2012).
23. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185(10), 1073-1080 (2012).
24. Huang YJ, Nelson CE, Brodie EL, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J. Allergy Clin. Immunol. 127(2), 372-381.e1 (2011).
25. Charlson ES, Chen J, Custers-Allen R, et al. Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS ONE 5(12), e15216 (2010).
26. Stressmann FA, Rogers GB, Klem ER, et al. Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers. J. Clin. Microbiol. 49(1), 281-291 (2011).
27. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 486(7402), 222-227 (2012).
28. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac diseasea clinical and pathologic study. Arch. Pediatr. Adolesc. Med. 56(2), 344-399 (1938).
29. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax 67(5), 456-463 (2012).
30. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23(2), 299-323 (2010).
31. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 41(8), 3548-3558 (2003).
32. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 42(11), 5176-5183 (2004).
33. Rogers GB, Carroll MP, Serisier DJ, et al. Bacterial activity in cystic fibrosis lung infections. Respir. Res. 6, 49 (2005).
34. Rogers GB, Carroll MP, Serisier DJ, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J. Clin. Microbiol. 44(7), 2601-2604 (2006).
35. Harris JK, De Groote MA, Sagel SD, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc. Natl Acad. Sci. USA 104(51), 20529-20533 (2007).
36. Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 3(8), e2908 (2008).
37. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 105(39), 15070-15075 (2008).
38. Armougom F, Bittar F, Stremler N, et al. Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. Eur. J. Clin. Microbiol. Infect. Dis. 28(9), 1151-1154 (2009).
39. Rogers GB, Daniels TW, Tuck A, et al. Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. BMC Pulm. Med. 9, 14 (2009).
40. Cox MJ, Allgaier M, Taylor B, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 5(6), e11044 (2010).
41. Doud MS, Light M, Gonzalez G, Narasimhan G, Mathee K. Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients. Hum. Genomics 4(3), 147-169 (2010).
42. Guss AM, Roeselers G, Newton IL, et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J. 5(1), 20-29 (2011).
43. Klepac-Ceraj V, Lemon KP, Martin TR, et al. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ. Microbiol. 12(5), 1293-1303 (2010).
44. Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD. Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 48(1), 78-86 (2010).
45. van der Gast CJ, Walker AW, Stressmann FA, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J. 5(5), 780-791 (2011).
46. Rudkjøbing VB, Thomsen TR, Alhede M, et al. True microbiota involved in chronic lung infection of cystic fibrosis patients found by culturing and 16S rRNA gene analysis. J. Clin. Microbiol. 49(12), 4352-4355 (2011).
47. Sibley CD, Grinwis ME, Field TR, et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS ONE 6(7), e22702 (2011).
48. Willner D, Haynes MR, Furlan M, et al. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J. 6(2), 471-474 (2012).
49. Daniels TW, Rogers GB, Stressmann FA, et al. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J. Cyst. Fibros. 12(1), 22-28 (2013).
50. Delhaes L, Monchy S, Fréalle E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS ONE 7(4), e36313 (2012).
51. Filkins LM, Hampton TH, Gifford AH, et al. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J. Bacteriol. 194(17), 4709-4717 (2012).
52. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 7(9), e45001 (2012).
53. Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc. Natl Acad. Sci. USA 109(34), 13769-13774 (2012).
54. Maughan H, Cunningham KS, Wang PW, et al. Pulmonary bacterial communities in surgically resected noncystic fibrosis bronchiectasis lungs are similar to those in cystic fibrosis. Pulm. Med. 2012, 746358 (2012).
55. Maughan H, Wang PW, Diaz Caballero J, et al. Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions. PLoS ONE 7(10), e45791 (2012).
56. Rudkjøbing VB, Thomsen TR, Alhede M, et al. The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients. FEMS Immunol. Med. Microbiol. 65(2), 236-244 (2012).
57. Stressmann FA, Rogers GB, van der Gast CJ, et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 67(10), 867-873 (2012).
58. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc. Natl Acad. Sci. USA 109(15), 5809-5814 (2012).
59. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123(5), 1495-1502 (2003).
60. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177(9), 995-1001 (2008).
61. Bruzzese E, Raia V, Spagnuolo MI, et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin. Nutr. 26(3), 322-328 (2007).
62. Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr. Pulmonol. 45(6), 536-540 (2010).
63. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Immunol. 1(1), 69-75 (2001).
64. Risnes KR, Belanger K, Murk W, Bracken MB. Antibiotic exposure by 6 months and asthma and allergy at 6 years: Findings in a cohort of 1,401 US children. Am. J. Epidemiol. 173(3), 310-318 (2011).
65. Alm JS, Swartz J, Lilja G, Scheynius A, Pershagen G. Atopy in children of families with an anthroposophic lifestyle. Lancet 353(9163), 1485-1488 (1999).
66. McKeever TM, Lewis SA, Smith C, et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. J. Allergy Clin. Immunol. 109(1), 43-50 (2002).
67. Wjst M, Hoelscher B, Frye C, Wichmann HE, Dold S, Heinrich J. Early antibiotic treatment and later asthma. Eur. J. Med. Res. 6(6), 263-271 (2001).
68. Droste JH, Wieringa MH, Weyler JJ, Nelen VJ, Vermeire PA, Van Bever HP. Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease? Clin. Exp. Allergy 30(11), 1547-1553 (2000).
69. Wickens K, Pearce N, Crane J, Beasley R. Antibiotic use in early childhood and the development of asthma. Clin. Exp. Allergy 29(6), 766-771 (1999).
70. Björkstén B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin. Exp. Allergy 29(3), 342-346 (1999).
71. Böttcher MF, Nordin EK, Sandin A, Midtvedt T, Björkstén B. Microflora-associated characteristics in faeces from allergic and nonallergic infants. Clin. Exp. Allergy 30(11), 1590-1596 (2000).
72. Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 107(1), 129-134 (2001).
73. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol. Med. Microbiol. 32(1), 1-7 (2001).
74. Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 108(4), 516-520 (2001).
75. Kirjavainen PV, Arvola T, Salminen SJ, Isolauri E. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut 51(1), 51-55 (2002).
76. Adlerberth I, Carlsson B, de Man P, et al. Intestinal colonization with Enterobacteriaceae in Pakistani and Swedish hospitaldelivered infants. Acta Paediatr. Scand. 80(6-7), 602-610 (1991).
77. Noverr MC, Falkowski NR, McDonald RA, McKenzie AN, Huffnagle GB. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect. Immun. 73(1), 30-38 (2005).
78. Noverr MC, Noggle RM, Toews GB, Huffnagle GB. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect. Immun. 72(9), 4996-5003 (2004).
79. Herbst T, Sichelstiel A, Schär C, et al. Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am. J. Respir. Crit. Care Med. 184(2), 198-205 (2011).
80. Stuart-Harris CH, Pownall M, Scothorne CM, Franks Z. The factor of infection in chronic bronchitis. Q. J. Med. 22(86), 121-132 (1953).
81. Tager I, Speizer FE. Role of infection in chronic bronchitis. N. Engl. J. Med. 292(11), 563-571 (1975).
82. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359(22), 2355-2365 (2008).
83. Albert RK, Connett J, Bailey WC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365(8), 689-698 (2011).
84. Huang YJ, Kim E, Cox MJ, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 14(1), 9-59 (2010).
85. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch. Intern. Med. 169(3), 219-229 (2009).
86. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 85(5), 771-774 (2008).
87. Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin. Respir. Infect. 17(4), 310-314 (2002).
88. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am. J. Respir. Crit. Care Med. 170(2), 181-187 (2004).
89. Charlson ES, Diamond JM, Bittinger K, et al. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am. J. Respir. Crit. Care Med. 186(6), 536-545 (2012).
90. Borewicz K, Pragman AA, Kim HB, Hertz M, Wendt C, Isaacson RE. Longitudinal analysis of the lung microbiome in lung transplantation. FEMS Microbiol. Lett. 339(1), 57-65 (2013).
91. Friaza V, la Horra Cd, Rodríguez-Domínguez MJ, et al. Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization. J. Microbiol. Methods 82(1), 98-101 (2010).
92. Flanagan JL, Brodie EL, Weng L, et al. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J. Clin. Microbiol. 45(6), 1954-1962 (2007).
93. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 111(5), 1266-1272 (1997).
94. Birring SS, Matos S, Patel RB, Prudon B, Evans DH, Pavord ID. Cough frequency, cough sensitivity and health status in patients with chronic cough. Respir. Med. 100(6), 1105-1109 (2006).
95. Munyard P, Bush A. How much coughing is normal? Arch. Dis. Child. 74(6), 531-534 (1996).
96. Worlitzsch D, Rintelen C, Böhm K, et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin. Microbiol. Infect. 15(5), 454-460 (2009).
97. Mccoll KEL. Helicobacter pylori infection. N. Engl. J. Med. 362(17), 1597-1604 (2010).
98. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112(5), 1442-1447 (1997).
99. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch. Intern. Med. 167(8), 821-827 (2007).
100. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut 52(5), 637-640 (2003).
101. Koch R. Untersuchungen ueber Bakterien V. Die Aetiologie der Milzbrand-Krankheit, begruendent auf die Entwicklungsgeschichte des Bacillus Anthracis. Beitr. z. Biol. D. Pflanzen 2, 277-310 (1876).
102. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 473(7346), 174-180 (2011).
103. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334(6052), 105-108 (2011).
104. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 336(6086), 1268-1273 (2012).
105. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl. Res. 160(4), 258-266 (2012).
106. Hughes DT, Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat. Rev. Microbiol. 6(2), 111-120 (2008).
107. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22(2), 299-306 (2012).
108. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22(2), 292-298 (2012).
109. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat. Rev. Rheumatol. 7(10), 569-578 (2011).
110. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307(18), 1959-1969 (2012).
111. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst. Rev. 2, CD003048 (2004).
112. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53(10), 994-1002 (2011).
113. Forsythe P. Probiotics and lung diseases. Chest 139(4), 901-908 (2011).
114. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am. J. Respir. Crit. Care Med. 182(8), 1058-1064 (2010).
115. Popova M, Molimard P, Courau S, et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J. Appl. Microbiol. 113(6), 1305-1318 (2012).
116. Yong E. Gut microbial 'enterotypes' become less clear-cut. www.nature.com/news/gut-microbialenterotypes-become-less-clear-cut-1.10276